Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

• Egile Nagusiak: Lieneke F.M. Ariëns (Egilea), Kirsten J.M. van Nimwegen (Egilea), Marjan Shams (Egilea), Digna T. de Bruin (Egilea), Jorien van der Schaft (Egilea), Harmieke van Os-Medendorp (Egilea), Marjolein De Bruin-Weller (Egilea)
• Formatua: Liburua
• Argitaratua: Medical Journals Sweden, 2019-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is needed. Direct costs (medication use and healthcare resource utilization) and costs of productivity loss were studied in 90 adult patients with...